Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Cindy Delbrook"'
Autor:
Brandon M. Wiley, Amita Kulshreshtha, Bonnie Yates, Daniel W. Lee, Stanislav Sidenko, Haneen Shalabi, Julia W. Cohen, Nirali N. Shah, Cindy Delbrook, Crystal L. Mackall, Vandana Sachdev, Doug R Rosing
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundChimeric antigen receptor (CAR) T-cell-associated cytokine release syndrome (CRS) may present with tachycardia, hemodynamic instability and reduced cardiac function. Pediatric CAR studies examining cardiac toxicity are limited.MethodsWe rep
Autor:
Eli Kane, Marie Claire Roderick, Staci Martin, Daniel W. Lee, Nirali N. Shah, Kari Struemph, Cindy Delbrook, Terry J. Fry, Crystal L. Mackall, Pamela L. Wolters, Haneen Shalabi, Mary Anne Toledo-Tamula, Bonnie Yates
Neurotoxicity associated with CAR-T cell therapy can be life-threatening. With rapid development of CAR-T therapies, a systematic method is needed to identify and monitor symptoms of neurotoxicity, elucidate potential etiologies, and compare toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ddd097f65f1a686bb2854d871ecc08c
https://europepmc.org/articles/PMC6086728/
https://europepmc.org/articles/PMC6086728/
Autor:
Crystal L. Mackall, Tolu Ariyo, Nirali N. Shah, David F. Stroncek, Terry J. Fry, Alan S. Wayne, Cindy Delbrook, David M. Loeb, Hahn Khuu, Mark Raffeld
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 22(12)
Relapse of hematologic malignancies is the primary cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HCT). Treatment for post-HCT relapse using donor lymphocyte infusion (DLI) has limited utility, particularly in th
Autor:
Steven A. Rosenberg, Constance M. Yuan, Marianna Sabatino, Terry J. Fry, Ling Zhang, Hua Zhang, Crystal L. Mackall, Rimas J. Orentas, Alan S. Wayne, Steven A. Feldman, Maryalice Stetler-Stevenson, James N. Kochenderfer, Dave Stroncek, Cindy Delbrook, Nick Tschernia, Nirali N. Shah, Seth M. Steinberg, Daniel W. Lee, Yongzhi K Cui
Publikováno v:
Lancet (London, England). 385(9967)
Summary Background Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and response rates of cons